Cantor Fitzgerald Reiterates Overweight on Ambrx Biopharma, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Ambrx Biopharma (NASDAQ:AMAM) and maintained a $25 price target.
September 18, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Ambrx Biopharma and maintained a $25 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Ambrx Biopharma. The maintained price target of $25 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100